{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T10:35:28Z","timestamp":1789900528317,"version":"4.0.1"},"reference-count":23,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,7,1]],"date-time":"2018-07-01T00:00:00Z","timestamp":1530403200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,7,1]],"date-time":"2018-07-01T00:00:00Z","timestamp":1530403200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Heart Journal"],"published-print":{"date-parts":[[2018,7]]},"DOI":"10.1016\/j.ahj.2018.04.005","type":"journal-article","created":{"date-parts":[[2018,4,6]],"date-time":"2018-04-06T18:24:58Z","timestamp":1523039098000},"page":"111-116","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"special_numbering":"C","title":["Design of a Phase 3 trial of intracoronary administration of human adenovirus 5 encoding human adenylyl cyclase type 6 (RT-100) gene transfer in patients with heart failure with reduced left ventricular ejection fraction: The FLOURISH Clinical Trial"],"prefix":"10.1016","volume":"201","author":[{"given":"William F.","family":"Penny","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy D.","family":"Henry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew W.","family":"Watkins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amit N.","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H. Kirk","family":"Hammond","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.ahj.2018.04.005_bb0005","first-page":"e28","article-title":"Heart Disease and Stroke Statistics \u2013 2014 Update: A Report from the American Heart Association","volume":"129","author":"Go","year":"2014","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2018.04.005_bb0010","series-title":"National Center for Health Statistics, Data Brief, No. 108","article-title":"Hospitalization for Congestive Heart Failure: United States, 2000-2010","author":"Hall","year":"2012"},{"key":"10.1016\/j.ahj.2018.04.005_bb0015","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1146\/annurev.pa.36.040196.002333","article-title":"Complexity and diversity of mammalian adenylyl cyclases","volume":"36","author":"Sunahara","year":"1996","journal-title":"Annu Rev Pharmacol Toxicol"},{"issue":"5","key":"10.1016\/j.ahj.2018.04.005_bb0020","doi-asserted-by":"crossref","first-page":"H1906","DOI":"10.1152\/ajpheart.00356.2004","article-title":"Adenylyl cyclase type VI corrects cardiac sarcoplasmic reticulum calcium uptake defects in cardiomyopathy","volume":"287","author":"Tang","year":"2004","journal-title":"Am J Physiol Heart Circ Physiol"},{"issue":"37","key":"10.1016\/j.ahj.2018.04.005_bb0025","doi-asserted-by":"crossref","first-page":"38797","DOI":"10.1074\/jbc.M405701200","article-title":"Adenylyl cyclase type VI gene transfer reduces phospholamban expression in cardiac myocytes via activating transcription factor","volume":"279","author":"Gao","year":"2004","journal-title":"J Biol Chem"},{"issue":"2","key":"10.1016\/j.ahj.2018.04.005_bb0030","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.bbrc.2009.04.110","article-title":"Activation of pH-domain leucine-rich protein phosphatase 2 (PHLPP2) by agonist stimulation in cardiac myocytes expressing adenylyl cyclase type 6","volume":"384","author":"Gao","year":"2009","journal-title":"Biochem Biophys Res Commun"},{"issue":"4","key":"10.1016\/j.ahj.2018.04.005_bb0035","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1056\/NEJM198207223070401","article-title":"Decreased catecholamine sensitivity and \u03b2-adrenergic\u2013receptor density in failing human hearts","volume":"307","author":"Bristow","year":"1982","journal-title":"N Engl J Med"},{"issue":"2, pt 2","key":"10.1016\/j.ahj.2018.04.005_bb0040","first-page":"H707","article-title":"Adenylyl cyclase and G protein receptor kinase expression during development of heart failure","volume":"273","author":"Ping","year":"1997","journal-title":"Am J Physiol"},{"issue":"5","key":"10.1016\/j.ahj.2018.04.005_bb0045","doi-asserted-by":"crossref","first-page":"2224","DOI":"10.1172\/JCI117219","article-title":"Downregulation of adenylyl cyclase types V and VI mRNA levels in pacing-induced heart failure in dogs","volume":"93","author":"Ishikawa","year":"1994","journal-title":"J Clin Invest"},{"issue":"11","key":"10.1016\/j.ahj.2018.04.005_bb0050","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1056\/NEJM198903163201101","article-title":"A comparison of oral milrinone, digoxin, and their combination in the treatment of patients with chronic heart failure","volume":"320","author":"DiBianco","year":"1989","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2018.04.005_bb0055","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1161\/01.CIR.0000136033.21777.4D","article-title":"Intracoronary adenovirus encoding adenylyl cyclase VI increases left ventricular function in heart failure","volume":"110","author":"Lai","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2018.04.005_bb0060","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1001\/jamacardio.2016.0008","article-title":"Intracoronary gene transfer of adenylyl cyclase 6 in patients with heart failure: A randomized clinical trial","volume":"1","author":"Hammond","year":"2016","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.ahj.2018.04.005_bb0065","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1161\/CIRCULATIONAHA.111.022889","article-title":"Calcium upregulation by percutaneous administration of gene therapy in cardiac disease (CUPID): a phase 2 trial of intracoronary gene therapy of sarcoplasmic reticulum Ca2+-ATPase in patients with advanced heart failure","volume":"124","author":"Jessup","year":"2011","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2018.04.005_bb0070","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1016\/S0140-6736(16)00082-9","article-title":"Calcium upregulation by percutaneous administration of gene therapy in patients with cardiac disease (CUPID 2): a randomised, multinational, double-blind, placebo-controlled, phase 2b trial","volume":"387","author":"Greenberg","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.ahj.2018.04.005_bb0075","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1161\/CIRCRESAHA.111.300440","article-title":"An open-label dose escalation study to evaluate the safety of administration of nonviral stromal cell-derived factor-1 plasmid to treat symptomatic ischemic heart failure","volume":"112","author":"Penn","year":"2013","journal-title":"Circ Res"},{"key":"10.1016\/j.ahj.2018.04.005_bb0080","doi-asserted-by":"crossref","first-page":"2228","DOI":"10.1093\/eurheartj\/ehv254","article-title":"Changes in ventricular remodelling and clinical status during the year following a single administration of stromal cell-derived factor-1 non-viral gene therapy in chronic ischaemic heart failure patients: the STOP-HF randomised Phase II trial","volume":"36","author":"Chung","year":"2015","journal-title":"Eur Heart J"},{"issue":"5","key":"10.1016\/j.ahj.2018.04.005_bb0085","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1089\/hum.2016.166","article-title":"Randomized clinical trials of gene transfer for heart failure with reduced ejection fraction","volume":"28","author":"Penny","year":"2017","journal-title":"Hum Gene Ther"},{"key":"10.1016\/j.ahj.2018.04.005_bb0090","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1161\/CIRCULATIONAHA.107.696906","article-title":"Influence of nonfatal hospitalization for heart failure on subsequent mortality in patients with chronic heart failure","volume":"116","author":"Solomon","year":"2007","journal-title":"Circulation"},{"issue":"3","key":"10.1016\/j.ahj.2018.04.005_bb0095","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.cardfail.2007.12.001","article-title":"Incident heart failure hospitalization and subsequent mortality in chronic heart failure: A propensity-matched study","volume":"14","author":"Ahmed","year":"2008","journal-title":"J Card Fail"},{"key":"10.1016\/j.ahj.2018.04.005_bb0100","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.cardfail.2008.10.029","article-title":"Unconventional end points in cardiovascular clinical trials: Should we be moving away from morbidity and mortality?","volume":"15","author":"Cohn","year":"2009","journal-title":"J Card Fail"},{"issue":"8","key":"10.1016\/j.ahj.2018.04.005_bb0105","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1016\/j.cardfail.2005.08.350","article-title":"Key issues in end point selection for heart failure trials: Composite end points","volume":"11","author":"Neaton","year":"2005","journal-title":"J Card Fail"},{"issue":"2","key":"10.1016\/j.ahj.2018.04.005_bb0110","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1093\/eurheartj\/ehr352","article-title":"The win ratio: A new approach to the analysis of composite endpoints in clinical trials based on clinical priorities","volume":"33","author":"Pocock","year":"2012","journal-title":"Eur Heart J"},{"issue":"22","key":"10.1016\/j.ahj.2018.04.005_bb0115","doi-asserted-by":"crossref","first-page":"2264","DOI":"10.1093\/eurheartj\/ehs277","article-title":"Time to move on from \u2018time-to-first\u2019: Should all events be included in the analysis of clinical trials?","volume":"33","author":"Anker","year":"2012","journal-title":"Eur Heart J"}],"container-title":["American Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002870318301121?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002870318301121?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T06:00:40Z","timestamp":1757570440000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002870318301121"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7]]},"references-count":23,"alternative-id":["S0002870318301121"],"URL":"https:\/\/doi.org\/10.1016\/j.ahj.2018.04.005","relation":{},"ISSN":["0002-8703"],"issn-type":[{"value":"0002-8703","type":"print"}],"subject":[],"published":{"date-parts":[[2018,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Design of a Phase 3 trial of intracoronary administration of human adenovirus 5 encoding human adenylyl cyclase type 6 (RT-100) gene transfer in patients with heart failure with reduced left ventricular ejection fraction: The FLOURISH Clinical Trial","name":"articletitle","label":"Article Title"},{"value":"American Heart Journal","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ahj.2018.04.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}